Sanbo Hospital Management Group Limited Class A

Sanbo Hospital Management Group Limited Class A

SSZSE:301293
49.50
CNY
-1.08
(-2.14%)
0.19EPS
147.34P/E
10.06BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.4
6.74
7.25
6.52
7.41
6.88
6.88
6.94
8.4
9.35
Basic EPS, GAAP
0.24
0.48
0.36
0.41
0.5
0.41
0.41
0.51
0.41
0.33
Free Cash Flow per Basic Share
0.27
0.71
0.69
-2.22
-0.15
0.4
0.4
-1.84
-1.94
- -
Dividend per Share
0.26
0.01
0.02
0.01
0.01
- -
- -
0.07
0.18
0.06
Book Value per Share
3.48
3.99
4.93
6.81
7.31
8.01
11.29
11.16
11.37
11.7
Tangible Book Value per Share
3.35
3.86
4.55
4.03
4.53
5.29
8.72
7.51
7.76
8.13
Basic Weighted Avg Shares
126
141
141
151
153
156
191
206
205
206
Sales/Revenue/Turnover
809
949
1,019
987
1,137
1,070
1,313
1,429
1,725
1,926
Operating Margin (%)
7.09
10.12
7.99
10.8
11.14
9.08
10.13
10.08
8.65
7.5
Depreciation Expense
26
27
27
30
72
82
77
77
109
- -
Net Income, GAAP
30
68
51
62
77
63
78
105
84
68
Effective Tax Rate (%)
45.01
26.75
34.65
21.8
23.47
22.08
28.55
23.65
39.54
57.61
Profit Margin (%)
3.73
7.19
4.99
6.25
6.74
5.93
5.96
7.35
4.88
3.54
Working Capital
283
346
461
450
409
399
1,291
414
82
231
LT Debt
- -
- -
- -
141
201
167
132
243
591
658
Total Equity
520
589
815
1,156
1,240
1,381
2,508
2,630
2,645
2,681
Return on Invested Capital (%)
- -
14.41
8.56
9.11
6.83
4.91
4.75
4.24
2.61
1.45
Return on Capital (%)
- -
12.39
7.28
5.16
6.64
3.83
3.7
3.6
3.38
3.28
Return on Common Equity (%)
- -
13.05
8.06
7.03
7.03
5.36
4.39
4.54
3.63
2.88

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
46
38
42
LT Borrowings
460
499
498
LT Finance Leases
167
159
160
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
206
206
206
Market Capitalization
13,434
9,924
10,062

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
660
687
742
Cash, Cash Equivalents & STI
438
433
485
Accounts Receivable, Net
122
158
146
Inventories
65
60
74
Total Current Liabilities
521
502
511
Payables & Accruals
- -
- -
- -
ST Debt
46
38
42
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
21.13%
0.58%
Free Cash Flow
- -
-208.06%
4.81%
Net Income, GAAP
- -
8.93%
-19.85%
Sales/Revenue/Turnover
- -
12.31%
20.69%
Total Cash Common Dividend
- -
539.95%
142.44%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
337
367
355
371
1,429
2025
393
434
- -
452
1,725
2026
445
526
503
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.16
0.19
- -
0.51
2025
0.19
0.15
- -
- -
0.41
2026
0.07
0.09
0.17
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.07
-0.02
- -
0.07
2025
- -
0.01
- -
0.01
0.18
2026
0.01
0.02
0.02
- -
- -

Company Description

CEO
Xiang Ying Xu
Full Time Employees
2,889
Sector
Health services
Industry
Hospital/Nursing management
Address
Beijing China
IPO Date
May 5, 2023
Website
sbnkjt.com
Business
Sanbo Hospital Management Group Limited is a China-based healthcare services company primarily engaged in the investment, operation, and management of specialized neurology hospitals and comprehensive medical institutions. Founded in 2003 and headquartered in Beijing, China, the company operates through an integrated clinical medical care, medical education, and scientific research business model, structured around a strong specialty, small comprehensive development framework. The company provides a comprehensive range of clinical and healthcare services, organized into specialized neurosurgical treatments, including brain tumor resection, skull base surgery, cerebrovascular bypass and vascular reconstructive surgery, functional neurosurgery for epilepsy and Parkinson's disease, spinal cord and vertebral surgery, and pediatric neurosurgery; neurological and neuro-oncological care, including neuro-intensive care, neuro-rehabilitation, clinical neurology, medical oncology, and stereotactic radiotherapy such as Gamma Knife surgery; neuro-interventional procedures, including endovascular coiling, embolization, and stenting for cerebrovascular disorders and aneurysms; general clinical medical services across internal medicine, general surgery, orthopedics, cardiology, intensive care, and emergency medicine; diagnostic and laboratory testing services, including neuroimaging, magnetic resonance imaging, computed tomography, digital subtraction angiography, video electroencephalography, and clinical pathology; and hospital management solutions, comprising healthcare investment management, medical technology consulting, hospital operating services, and medical facility management. The company delivers its medical services across major metropolitan and regional markets in China through an expanding hospital network that includes Capital Medical University Sanbo Brain Hospital in Beijing, Chongqing Sanbo Chang'an Hospital, Chongqing Sanbo Jiangling Hospital, Kunming Sanbo Brain Hospital, Luoyang 511 Sanbo Brain Hospital, Xi'an Sanbo Brain Hospital, and Chengdu Dongli Hospital. In recent corporate developments, the company listed its Class A shares on the Shenzhen Stock Exchange ChiNext board under ticker symbol 301293. As part of its strategic nationwide expansion, the company acquired a 70% controlling interest in Sichuan Daxing Guangze Medical Investment Management Co., Ltd. for 420 million yuan, expanding its healthcare network into southwestern China through Chengdu Dongli Hospital. Furthermore, the company completed the relocation and capacity upgrade of its flagship Beijing Sanbo Brain Hospital to its new Dongba campus, expanding total operational capacity to 480 beds and adding specialized radiotherapy and rehabilitation departments; officially opened the newly constructed Xi'an Sanbo Brain Hospital; completed the relocation and opening of the expanded Kunming Sanbo Brain Hospital facility; and advanced development of the Hunan Sanbo Brain Hospital project. The company has also expanded its translational medical research initiatives through academic collaborations with institutions such as Tsinghua University and participation in clinical research trials evaluating interventional brain-computer interface technologies for neurological and motor rehabilitation.